Immunology

Human trials begin of investigational HIV prime-boost vaccine candidates

Published in TB and Outbreaks Week, October 14th, 2003

Aventis and Merck & Co., Inc., announced human trials have begun to test the safety and immune responses generated by using a combination of two anti-HIV-1 vaccine candidates in a complementary way.

The collaborative phase I study looks at a prime-boost regimen that in an earlier preclinical investigation in monkeys found a higher level of immune response against HIV-1 than either vaccine used separately. Phase I represents the earliest stage of human testing for a potential vaccine.

The prime-boost regimen uses Merck's replication-defective adenovirus type 5 vector (Ad5) vaccine candidate first, followed by the canarypox virus vector (ALVAC) vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-10-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry